ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v17i6.2200ppharm-1922Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESАнализ вакцинального анамнеза детей, перенесших инфекцию, вызванную SARS-CoV-2Analysis of Vaccination Background in Children Undergone SARS-CoV-2 Infectionhttps://orcid.org/0000-0003-0797-5612ФедосеенкоМ. В.FedoseenkoMarina V.

Федосеенко Марина Владиславовна, кандидат медицинских наук, доцент кафедры факультетской педиатрии педиатрического факультета ФГБУ ВО РНИМУ имени Н.И. Пирогова Минздрава России, заведующая отделом разработки научных подходов к иммунизации пациентов с отклонениями в состоянии здоровья и хроническими болезнями, ведущий научный сотрудник, врач-педиатр НИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования РФ

119333, Москва, ул. Фотиевой, д. 10

тел.: +7 (499) 400-47-33

Moscow

titovamarina@mail.ruhttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Москва, Белгород

Moscow, Belgorod

https://orcid.org/0000-0002-3270-4374ШахтахтинскаяФ. Ч.ShakhtakhtinskayaFiruza Ch.

Москва

Moscow

ФоминыхМ. В.FominykhM. V.

Москва

Moscow

https://orcid.org/0000-0003-1453-4671КалюжнаяТ. А.KalyuzhnayaTatiana A.

Москва

Moscow

https://orcid.org/0000-0003-4680-2925ПриваловаТ. Е.PrivalovaTatiana E.

Москва

Moscow

https://orcid.org/0000-0002-1215-1872РусиноваД. С.RusinovaDina S.

Москва

Moscow

СельвянА. М.Sel’vyanA. M.

Москва

Moscow

ТолстоваС. В.TolstovaSvetlana V.

Москва

Moscow

НИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования РФ; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияResearch Institute of Pediatrics and Children’s Health in «Central Clinical Hospital of the Russian Academy of Sciences»; Pirogov Russian National Research Medical UniversityRussian FederationНИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования РФ; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова; Белгородский государственный национальный исследовательский университетРоссияResearch Institute of Pediatrics and Children’s Health in «Central Clinical Hospital of the Russian Academy of Sciences»; Pirogov Russian National Research Medical University; Belgorod State National Research UniversityRussian FederationНИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования РФРоссияResearch Institute of Pediatrics and Children’s Health in «Central Clinical Hospital of the Russian Academy of Sciences»Russian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова; Детская городская поликлиника № 133 Департамента здравоохранения города МосквыРоссияPirogov Russian National Research Medical University; Children’s City Outpatient’s Clinic № 133 of Moscow City Health DepartmentRussian Federation202026012021176508518Copyright © Федосеенко М.В., Намазова-Баранова Л.С., Шахтахтинская Ф.Ч., Фоминых М.В., Калюжная Т.А., Привалова Т.Е., Русинова Д.С., Сельвян А.М., Толстова С.В., 20212021Федосеенко М.В., Намазова-Баранова Л.С., Шахтахтинская Ф.Ч., Фоминых М.В., Калюжная Т.А., Привалова Т.Е., Русинова Д.С., Сельвян А.М., Толстова С.В.Fedoseenko M.V., Namazova-Baranova L.S., Shakhtakhtinskaya F.C., Fominykh M.V., Kalyuzhnaya T.A., Privalova T.E., Rusinova D.S., Sel’vyan A.M., Tolstova S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/1922

На сегодняшний день новости о коронавирусной инфекции нового типа вызывают большой интерес и озабоченность специалистов во всем мире. По имеющимся в настоящее время данным, дети часто не подвержены воздействию вируса, вызывающего COVID-19, или имеют только легкое течение заболевания. Эти данные также могут объяснить, почему у детей гораздо более низкий уровень заболеваемости COVID-19, чем у взрослых. Полученные в ходе проведенных разными группами исследователей эпидемиологических наблюдений результаты о вероятно «защитном» действии прививок рутинных программ вакцинопрофилактики в отношении коронавирусной инфекции нового типа способствовали инициации клинических исследований. В данной публикации представлены анализ вакцинального статуса и характеристики прививочного и других видов анамнеза у 143 московских детей, перенесших инфекцию, вызванную SARS-CoV-2. В целом общий вакцинальный анамнез у детей, перенесших COVID-19, характеризуется низким уровнем привитости и несоответствием Национальному календарю профилактических прививок. Наиболее неблагополучный вакцинальный анамнез отмечен у детей раннего возраста. Уровень вакцинации у всех детей первого года жизни (в 100% случаев) отличался отставанием от рутинного графика. Самый низкий уровень полноценной вакцинации регистрировался в отношении вирусного полиомиелита — у 30% детей — реконвалесцентов коронавирусной инфекции нового типа. Подавляющее большинство детей, переболевших COVID-19, не были вакцинированы против гриппа, лишь единицы были привиты против пневмококковой инфекции. В настоящее время про- водится целый ряд исследований, направленных на изучение защитной роли вакцин в отношении заболеваемости и тяжелого течения коронавирусной инфекции нового типа.

Nowadays all news about the new coronavirus disease type arouses interest and concern among specialists around the world. Children often are not exposed to the COVID-19 virus or they just have mild course of the disease according to currently available data. These data may also explain why children have much lower incidence of COVID-19 in comparison to adults. The results of epidemiological observations performed by different researchers’ groups on the likely “protective” effect of routine vaccine prevention programs against new type of coronavirus disease led to initiation of clinical studies. This article presents the analysis of the vaccinal status and characteristics of vaccination and any other background in 143 Moscow children undergone SARS-CoV-2 infection. Overall, the general vaccination background in children who have undergone COVID-19 is characterized with low vaccination level and mismatch with the National Immunization Schedule. The most unfavorable vaccination background was mentioned in infants. The vaccination rate in all children of the first year of life (in 100% of cases) had gap to the routine schedule. The lowest rate of appropriate vaccination was recorded in case of viral poliomyelitis (in 30% of children) in reconvalescents new type of coronavirus disease. The vast majority of children undergone COVID-19 were not vaccinated against flue, only a few were vaccinated against pneumococcal infection. Now there are several studies focused on determining the protective role of vaccines in relation to the new type of coronavirus disease morbidity and course severity.

вакцинацияпандемиякоронавирусная инфекцияCOVID-19иммунитетпрофилактикаvaccinationpandemiccoronavirus diseaseCOVID-19immunitypreventionReferencesEscobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). PNAS. 2020;117(30):17720–17726. doi: 10.1073/pnas.2008410117Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). PNAS. 2020;117(30):17720–17726. doi: 10.1073/pnas.2008410117Hegarty P-K, Kamat A, Zafirakis H, DiNardo A. BCG vaccination may be protective against Covid-19. Preprint March 2020. doi: 10.13140/RG.2.2.35948.10880Hegarty P-K, Kamat A, Zafirakis H, DiNardo A. BCG vaccination may be protective against Covid-19. Preprint March 2020. doi: 10.13140/RG.2.2.35948.10880Dolgikh S. Further Evidence of a Possible Correlation Between the Severity of Covid-19 and BCG Immunization. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.07.20056994Dolgikh S. Further Evidence of a Possible Correlation Between the Severity of Covid-19 and BCG Immunization. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.07.20056994WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https://covid19.who.int. Accessed on January 14, 2021.WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https://covid19.who.int. Accessed on January 14, 2021.Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473–1478. doi: 10.1016/j.cmi.2019.04.020Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473–1478. doi: 10.1016/j.cmi.2019.04.020Miller A, Reandelar M-J, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. Preprint March 2020. doi: 10.1101/2020.03.24.20042937Miller A, Reandelar M-J, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. Preprint March 2020. doi: 10.1101/2020.03.24.20042937Sala G, Miyakawa T. Association of BCG vaccination policy with prevalence and mortality of COVID-19. medRxiv. Preprint May 2020. doi: 10.1101/2020.03.30.20048165Sala G, Miyakawa T. Association of BCG vaccination policy with prevalence and mortality of COVID-19. medRxiv. Preprint May 2020. doi: 10.1101/2020.03.30.20048165Shet A, Ray D, Malavige N, et al. Differential COVID-19-attributable mortality and BCG vaccine use in countries. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.01.20049478Shet A, Ray D, Malavige N, et al. Differential COVID-19-attributable mortality and BCG vaccine use in countries. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.01.20049478Berg MK, Yu Q, Salvador CE, et al. Mandated BCG vaccination predicts flattened curves for the spread of COVID-19. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.05.20054163Berg MK, Yu Q, Salvador CE, et al. Mandated BCG vaccination predicts flattened curves for the spread of COVID-19. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.05.20054163K. Chumakov K., Benn CS, Aaby P, et al. Can existing live vaccines prevent COVID-19? Science. 2020;368(6496):1187–1188. doi: 10.1126/science.abc4262K. Chumakov K., Benn CS, Aaby P, et al. Can existing live vaccines prevent COVID-19? Science. 2020;368(6496):1187–1188. doi: 10.1126/science.abc4262Riccò M, Gualerzi G, Ranzieri S, Bragazzi NL. Stop playing with data: there is no sound evidence that Bacille Calmette-Guérin may avoid SARS-CoV-2 infection (for now). Acta Biomed. 2020;91(2):207–213. doi: 10.23750/abm.v91i2.9700Riccò M, Gualerzi G, Ranzieri S, Bragazzi NL. Stop playing with data: there is no sound evidence that Bacille Calmette-Guérin may avoid SARS-CoV-2 infection (for now). Acta Biomed. 2020;91(2):207–213. doi: 10.23750/abm.v91i2.9700Miyasaka M. Is BCG vaccination causally related to reduced COVID-19 mortality? EMBO Mol Med. 2020;12(6):e12661. doi: 10.15252/emmm.202012661Miyasaka M. Is BCG vaccination causally related to reduced COVID-19 mortality? EMBO Mol Med. 2020;12(6):e12661. doi: 10.15252/emmm.202012661Redelman-Sidi G. Could BCG be used to protect against COVID-19? Nat Rev Urol. 2020;17(6):316–317. doi: 10.1038/s41585-020-0325-9Redelman-Sidi G. Could BCG be used to protect against COVID-19? Nat Rev Urol. 2020;17(6):316–317. doi: 10.1038/s41585-020-0325-9БЦЖ вакцины: документ по позиции ВОЗ — февраль 2018 // Еженедельный эпидемиологический бюллетень. — 2018. Т. 93. — № 8. С. 73–96.BCG vaccines: WHO position paper — February, 2016. Weekly epidemiological record. 2018;93(6):73–96. (In Russ).Глобальный отчет по туберкулезу 2020 г.: резюмеGlobal tuberculosis report 2020: executive summary (In Russ)..A database of global BCG Vaccination policies and practices. BCG World Atlas. Available online: bcgatlas.org. Accessed on January 14, 2021.A database of global BCG Vaccination policies and practices. BCG World Atlas. Available online: bcgatlas.org. Accessed on January 14, 2021.Dayal D., Gupta S. Connecting BCG Vaccination and COVID-19: Additional Data. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.07.20053272Dayal D., Gupta S. Connecting BCG Vaccination and COVID-19: Additional Data. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.07.20053272Mangtani P, Nguipdop-Djomo P, Keogh RH, et al. Observational study to estimate the changes in the effectiveness of bacillus Calmette–Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technol Assess. 2017;21(39):1–54. doi: 10.3310/hta21390Mangtani P, Nguipdop-Djomo P, Keogh RH, et al. Observational study to estimate the changes in the effectiveness of bacillus Calmette–Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technol Assess. 2017;21(39):1–54. doi: 10.3310/hta21390Barreto ML, Cunha SS, Pereira SM, et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung Dis. 2005;9(10):1171–1173.Barreto ML, Cunha SS, Pereira SM, et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung Dis. 2005;9(10):1171–1173.Nguipdop-Djomo P, Heldal E, Rodrigues LC, et al. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis. 2016;16(2):219–226. doi: 10.1016/S1473-3099(15)00400-4Nguipdop-Djomo P, Heldal E, Rodrigues LC, et al. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis. 2016;16(2):219–226. doi: 10.1016/S1473-3099(15)00400-4Aronson N, Santosham M, Comstock GW, et al. Long-term Efficacy of BCG Vaccine in American Indians and Alaska Natives A 60-Year Follow-up Study. JAMA. 2004;291(17):2086–2091. doi: 10.1001/jama.291.17.2086Aronson N, Santosham M, Comstock GW, et al. Long-term Efficacy of BCG Vaccine in American Indians and Alaska Natives A 60-Year Follow-up Study. JAMA. 2004;291(17):2086–2091. doi: 10.1001/jama.291.17.2086Шварц Я.Ш., Ставицкая Н.В., Кудлай Д.А. BCG-вакцинирование как протекция от COVID-19: эпидемиологические и молекулярно-биологические аспекты // Туберкулез и болезни легких. — 2020. — Т. 98. — № 5. — С. 6–14.Shvаrts YaSh, Stаvitskаya NV, Kudlay DA. BCG vaccination as protection from COVID-19: epidemiological and molecular biological aspectsю . Tuberculosis and Lung Diseases. 2020;98(5):6–14. (In Russ). doi: 10.21292/2075-1230-2020-98-5-6-14Art RJW, Carvalho A, La Rocca C, et al. Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep. 2016;17(10):2562– 2571. doi: 10.1016/j.celrep.2016.11.011Art RJW, Carvalho A, La Rocca C, et al. Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep. 2016;17(10):2562– 2571. doi: 10.1016/j.celrep.2016.11.011Floc’h F, Werner GH. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guerin). Ann Immunol. 1976;127(2):173–186.Floc’h F, Werner GH. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guerin). Ann Immunol. 1976;127(2):173–186.Spencer JC, Ganguly R, Waldman RH. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette–Guerin. J Infect Dis. 1977;136(2):1–175. doi: 10.1093/infdis/136.2.171Spencer JC, Ganguly R, Waldman RH. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette–Guerin. J Infect Dis. 1977;136(2):1–175. doi: 10.1093/infdis/136.2.171Wardhana EA, Datau EA, Sultana A, et al. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43:185–190.Wardhana EA, Datau EA, Sultana A, et al. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43:185–190.Bacillus Calmette-Guérin vaccination to prevent infections of the elderly (ACTIVATE). US National Library of Medicine ClinicalTrials.gov. First Posted: September 28, 2017. Last Update Posted: January 11, 2021. Available online: https://clinicaltrials.gov/ct2/show/record/NCT03296423. Accessed on January 14, 2021.Bacillus Calmette-Guérin vaccination to prevent infections of the elderly (ACTIVATE). US National Library of Medicine ClinicalTrials.gov. First Posted: September 28, 2017. Last Update Posted: January 11, 2021. Available online: https://clinicaltrials.gov/ct2/show/record/NCT03296423. Accessed on January 14, 2021.Lopez-Campos G;, Hawthorne Christopher Hawthorne1, Valvano MSc; and Miguel A. ValvanoThe BCG dilemma: linear versus non-linear correlation models over the time of the COVID-19 pandemic. medRxiv. Preprint June 2020 doi: 10.1101/2020.06.13.20129569Lopez-Campos G;, Hawthorne Christopher Hawthorne1, Valvano MSc; and Miguel A. ValvanoThe BCG dilemma: linear versus non-linear correlation models over the time of the COVID-19 pandemic. medRxiv. Preprint June 2020 doi: 10.1101/2020.06.13.20129569Sayed A, Challa K, Arja S. Epidemiological Differences of COVID-19 Over the World. Cureus. 2020;12(9):e10316. doi: 10.7759/cureus.10316Sayed A, Challa K, Arja S. Epidemiological Differences of COVID-19 Over the World. Cureus. 2020;12(9):e10316. doi: 10.7759/cureus.10316Prasad R. Singh A, Gupta N. Tuberculosis and COVID 19 in India: Challenges and opportunities. Lung India. 2020;37(4):292– 294. doi: 10.4103/lungindia.lungindia_260_20Prasad R. Singh A, Gupta N. Tuberculosis and COVID 19 in India: Challenges and opportunities. Lung India. 2020;37(4):292– 294. doi: 10.4103/lungindia.lungindia_260_20Ordog G-J. BCG Comments JAMA, by Ordog: SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA. May 15, 2020. doi: 10.1001/jama.2020.8189commentOrdog G-J. BCG Comments JAMA, by Ordog: SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA. May 15, 2020. doi: 10.1001/jama.2020.8189commentReducing health care workers absenteeism in COVID-19 pandemic through BCG vaccine (BCG-CORONA). US National Library of Medicine ClinicalTrials.gov. First Posted: March 31, 2020. Last Update Posted: August 19, 2020. Available online:https://clinicaltrials.gov/ct2/show/NCT04328441. Accessed on January 14, 2021.Reducing health care workers absenteeism in COVID-19 pandemic through BCG vaccine (BCG-CORONA). US National Library of Medicine ClinicalTrials.gov. First Posted: March 31, 2020. Last Update Posted: August 19, 2020. Available online:https://clinicaltrials.gov/ct2/show/NCT04328441. Accessed on January 14, 2021.BCG vaccination to protect healthcare workers against COVID-19 (BRACE). US National Library of Medicine ClinicalTrials. gov. First Posted: March 31, 2020. Last Update Posted: October 22, 2020. Available online: https://clinicaltrials.gov/ct2/show/NCT04327206. Accessed on January 14, 2021.BCG vaccination to protect healthcare workers against COVID-19 (BRACE). US National Library of Medicine ClinicalTrials. gov. First Posted: March 31, 2020. Last Update Posted: October 22, 2020. Available online: https://clinicaltrials.gov/ct2/show/NCT04327206. Accessed on January 14, 2021.Guven R, Sasmaz MI, Eyupoglu G, Semerci SY. Do childhood measles and DTaP vaccination decrease the mortality rate caused by SARS CoV-2 in OECD countries? An Epidemiologic Study. Research Square. Preprint July 2020. doi: 10.21203/rs.3.rs-48106/v1Guven R, Sasmaz MI, Eyupoglu G, Semerci SY. Do childhood measles and DTaP vaccination decrease the mortality rate caused by SARS CoV-2 in OECD countries? An Epidemiologic Study. Research Square. Preprint July 2020. doi: 10.21203/rs.3.rs-48106/v1Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol. 1989;36:191–202.Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol. 1989;36:191–202.Chumakov MP, Voroshilova MK, Antsupova AS, et al. Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol. 1992;(11–12):37–40.Chumakov MP, Voroshilova MK, Antsupova AS, et al. Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol. 1992;(11–12):37–40.Cauchi S, Locht C. Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases. Front Immunol. 2018;9:2872. doi: 10.3389/fimmu.2018.02872Cauchi S, Locht C. Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases. Front Immunol. 2018;9:2872. doi: 10.3389/fimmu.2018.02872Aaby P, Benn CS. Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. Clin Microbiol Infect. 2019;25(12):1459–1467. doi: 10.1016/j.cmi.2019.08.011Aaby P, Benn CS. Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. Clin Microbiol Infect. 2019;25(12):1459–1467. doi: 10.1016/j.cmi.2019.08.011Zheng MY, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi: 10.1038/s41423-020-0402-2Zheng MY, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi: 10.1038/s41423-020-0402-2Götzinger F., Begoña Santiago-García Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020; 4(9): 653–61. doi: 10.1016/S2352-4642(20)30177-2Götzinger F., Begoña Santiago-García Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020; 4(9): 653–61. doi: 10.1016/S2352-4642(20)30177-2Sabir DK, Khwarahm NR, Ali SM, et al. Children Protection Against COVID-19 at the Pandemic Outbreak. J Immunological Sci. 2020;4(2):8–12. doi: 10.29245/2578-3009/2020/2.118.8Sabir DK, Khwarahm NR, Ali SM, et al. Children Protection Against COVID-19 at the Pandemic Outbreak. J Immunological Sci. 2020;4(2):8–12. doi: 10.29245/2578-3009/2020/2.118.8

The authors declare that there are no conflicts of interest present.